NTT Wins Fast Company World Changing Ideas Award for Project Humanity
Project Humanity exemplifies NTT's commitment to conducting fundamental research and development to create technology that betters health, wellbeing, connection and society for all, including through the work of NTT R&D and NTT Research labs.
Share
'Project Humanity is a revolutionary system intended to give more physical freedom to people with disabilities and enable them to engage with society more meaningfully,' reads Project Humanity's entry on Fast Company's 2025 list of 100 winning projects. 'An interface converts EMG signals—which are generated by contracting muscles—into control signals for use on various digital platforms. It's an intuitive communication method for people with limited mobility, particularly those with ALS.'
Muto Masatane is a DJ living with Amyotrophic Lateral Sclerosis (ALS) and founder of the advocacy organization WITH ALS. Masatane has utilized Project Humanity to perform concerts live and in the metaverse via a digital avatar, including at SXSW 2024. In addition, NTT hosted "DE & I eSports," an inclusive event that allowed people living with Spinal Muscular Atrophy (SMA) and Muscular Dystrophy to interact remotely from their homes in Japan with able-bodied people at venues in Japan and France.
Looking ahead, developers plan to expand the technology's use cases to improve day-to-day opportunities for those living with disabilities, including creating greater access to education via virtual classrooms, realizing richer communication capabilities for those living with ALS, supporting the movement of people with spinal cord injuries and further supporting the encouragement of participation for people with dementia.
NTT: Innovating for a Better Future for All
Fast Company's World Changing Ideas Awards celebrate innovative ideas and projects that make the world a better place, including through social impact, environmental awareness, technological innovation and social equity. Project Humanity exemplifies NTT's commitment to conducting fundamental research and development to create technology that betters health, wellbeing, connection and society for all, including through the work of NTT R&D and NTT Research labs.
For example, NTT's Innovative Optical and Wireless Network (IOWN) All-Photonics Network recently connected performers in Japan and Taiwan at Osaka Expo 2025 for a first-of-its-kind, real-time co-production of a traditional kabuki performance using the APN's ultra-low latency and ultra-low power capabilities. The company also announced in April the successful demonstration of a world-first drone capable of triggering, guiding and 'catching' lightning to protect individuals and infrastructure from dangerous lightning strikes.
At Upgrade 2025, NTT Research, the Silicon Valley-based fundamental research arm of NTT, announced the creation of the Physics of Artificial Intelligence (PAI) Group dedicated to studying the 'black box' nature of AI and machine learning to develop more trustworthy, safe and sustainable AI-based systems. Additionally, NTT Research's Medical & Health Informatics (MEI) Lab is advancing the creation of a cardiovascular bio digital twin to improve precision healthcare, including through the Autonomous Closed-Loop Intervention System (ACIS). ACIS improves the treatment of severe cardiac events by autonomously optimizing and administering multiple cardiac drugs and therapies simultaneously.
In 2024, NTT, NTT DATA and NTT R&D deployed Embodied Knowledge technology at the Indianapolis 500 automotive race. This cybernetic technology powered simulators that allowed users to experience the track in extended reality (XR) as driven by professional drivers, exceeding the capabilities of traditional simulators by adding factors like realistic steering wheel forces, driver seat forces and car vibrations. But, researchers expect Embodied Knowledge technology to have a diverse range of future use cases, including medical surgery training, employee training in fields like retail and manufacturing and enabling AI robots to move and react more like humans (better serving functions such as in-home caregiving).
For more information about Project Humanity, please visit:
For more information about NTT's R&D initiatives, please visit:
About NTT
NTT contributes to a sustainable society through the power of innovation. We are a leading global technology company providing services to consumers and businesses as a mobile operator, infrastructure, networks, applications, and consulting provider. Our offerings include digital business consulting, managed application services, workplace and cloud solutions, data center and edge computing, all supported by our deep global industry expertise. We are over $90B in revenue and 340,000 employees, with $3B in annual R&D investments. Our operations span across 80+ countries and regions, allowing us to serve clients in over 190 of them. We serve over 75% of Fortune Global 100 companies, thousands of other enterprise and government clients and millions of consumers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
3 days ago
- Fast Company
Companies need leaders. Here's how to stand out
Companies are struggling with the rise of AI, high levels of employee burnout, and managing hybrid teams. Now, there's a new challenge: no one wants to be a leader. According to DDI's 2025 HR Insights report, based on a survey of 2,185 HR professionals and 10,796 leaders, 75% of companies prioritize promoting employees to leadership roles from within. However, less than 20% of Chief Human Resource Officers say they actually have employees who are ready to fill critical leadership roles. On average, there are only enough internal candidates to fill less than half (49%) of open leadership positions. Going forward, it looks like the leadership vacuum is likely to get worse. According to the report, Gen Z is 1.4 times more likely than other generations to reject a leadership role. At the same time, Gen Z is also 2.8 times more likely to quit a job because of subpar leadership. However, as Fast Company contributor Tracey Brower points out, the dearth of qualified candidates creates an opportunity for anyone who wants to be a leader. What can companies do to create more leaders? Historically, leadership roles have been desirable but as navigating the business landscape becomes more complicated, leadership roles have become less attractive. 'Leadership is becoming a tougher job every day,' said Tacy M. Byham, Ph.D., CEO of DDI, in a press release. 'While organizations can't control the deluge of external challenges they face this year, strategic HR executives can build resilience by using trusted people analytics to forecast needs, build their bench, and reinvigorate the next generation of leaders.' Essentially, companies need to create a strong leadership pipeline. Promotions are six times more likely when employees receive adequate coaching from managers. Likewise, companies should always be thinking about their strongest employees' potential, even before leadership positions become available. Tara Rasmussen, a hiring manager for Hapi, a hospitality tech company, points out that employee expectations have evolved. While she says older professionals cling to habits like 'micromanagement' and 'habits of overworking,' young employees are pushing back—even those who want to be leaders are setting firm boundaries around their personal time. 'Elder millennials and Gen Z employees are more inclined to say 'No thanks' to giving up personal time even with decent salary increases,' she explains. In the past while future leaders stood out by working long hours, today selection committees need to understand that even leaders want time off. What can employees looking for leadership roles do to stand out? Cultivate soft skills Strong leadership is built on a solid foundation of soft skills. Rasmussen, notes that when it comes to new leadership, 'soft skills,' like communication and interpersonal skills, are more important than ever before. She notes that soft skills are the ability to navigate nuance while communicating with others and doing work. It's not a one way lane,' Rasmussen explains. 'Leaders in the current climate cannot expect to step into a role and communicate one way to all team members and be successful because everyone is different.' Humility Given the current environment where leaders face all kinds of challenges from technological changes to a turbulent economy, Rasmussen also points out 'humility' is a key attribute modern leaders must have. 'The ability to say, 'I don't know but I'll find out,' is absolutely critical,' she explains. 'Leaders we look for now are not just 'bosses' that micromanage and order employees around. They must be able to be, well, human. Admit when wrong and grow alongside their teams.' Embracing AI and adaptability Jeffrey Pole, CEO and cofounder of Warden AI, tells Fast Company that, in 2025, leaders have to be innovative, adaptable, and knowledgeable about how to work alongside AI. 'There is much fear in the workforce today, with economic uncertainty, technology disruption, and a constant need for new skills and new career paths,' Pole explains. 'The best leaders of this generation will be the ones who can adapt to change, embrace new opportunities, and motivate people to explore and experiment with the technologies and markets that are opening up.'
Newsweek
3 days ago
- Newsweek
Watch: Moment Woman With ALS Recovers Voice With AI
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Debbie Lopez lost her voice to a muscle-weakening disease, but with the help of new artificial intelligence (AI) technology, she is speaking to her family again, Monroe Community Hospital (MCH) in Rochester, New York, confirmed to Newsweek. Why It Matters Lopez, who has been a patient at MCH since February, was diagnosed with ALS (amyotrophic lateral sclerosis) in 2019. ALS is a disease that affects the nerve cells in the body, causing the muscles to become weak and can lead to paralysis and loss of voice. No singular cause has been identified for most causes of ALS, with some research into factors that may be linked, such as heredity, environmental exposures, and diet, among others. About 30,000 people in the United States are living with ALS, according to estimates from the Centers for Disease Control and Prevention, which notes that tracking the disease can be challenging. AI technology is rapidly transforming society, reshaping jobs, productivity and advancements across sectors, including medicine. What to Know Several years ago, Lopez, 39, started a YouTube channel, Living with Lemons, to document her health journey, raise awareness, and provide comfort to others going through a similar experience. The channel has ended up being able to give Lopez her voice back, as speech pathologist Jaime Spencer, who provides care to Lopez at MCH explained, "We were able to get her voice from using her YouTube channel," adding, "and from there they were able to clone anything that she wants to say." The AI voice, which mirrors Lopez's, can now mimic anything Lopez types, thanks to the content from her YouTube videos and the technology's ability to replicate speech. MCH shared with Newsweek a video of Lopez breaking into a smile as she hears her voice from the device, saying in what sounds just like her, "Hi, I am Debbie Lopez." A screen grab of a Monroe Community Hospital video showing Debbie Lopez, a patient with ALS, hearing her voice from AI. A screen grab of a Monroe Community Hospital video showing Debbie Lopez, a patient with ALS, hearing her voice from AI. Monroe Community Hospital Lopez uses an Eyegaze device to control what the AI says, allowing her to direct and select items with her eyes, send messages and surf the web, among other features. "Cameras on the device track her eye movements and she can look at different parts of her monitor for either letters, words, or popular phrases or presets she has on her communications device," an MCH spokesperson told Newsweek in an email Wednesday. In the MCH video explaining Lopez's health journey and the use of the AI, Spencer said, "This new software and this new technology has been amazing because it allows patients and individuals to preserve some of the most intimate parts of them and what makes you you, is your voice." Lopez, through the AI, says in the video, "Even if I can't make a sound, I still have a voice." Lopez and her team at MCH are working on preserving her voice for her three children and family members by reading and recording some of her favorite children's books. What Happens Next Lopez remains in high spirits despite the severity of her disease, saying, "It's broken everyone who loves me and everyone I love, but it hasn't broken me," and adding, "I get to see the best in everyone." AI is increasingly being used in medical settings, from diagnostics and predictive analytics to assisted surgeries and the development of new treatments. "ALS can be pretty isolating. Patients lose function of much of their body parts. Anything that helps restore a sense of normalcy is a huge benefit," a MCH spokesperson told Newsweek.
Yahoo
4 days ago
- Yahoo
Financing Innovation: Proposal for Novel Adaptive Platform Trial Fund Offers New Model for ALS Drug Development
Researchers propose new royalty-based investment model to bridge the 'valley of death' and accelerate drug development New royalty-based investment model for ALS drug development Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), Questrom School of Business at Boston University, and QLS Advisors have introduced a new approach to funding clinical trials for amyotrophic lateral sclerosis (ALS) therapies. The study 'Financing Drug Development via Adaptive Platform Trials,' published today in PLOS One, outlines a financing model that merges the efficiencies of adaptive platform trials — lower costs and shorter durations — with an innovative royalty-based investment structure designed to accelerate therapeutic development for ALS and other serious — also often called Lou Gehrig's disease — is a progressive, neurodegenerative disease with no cure. Despite its devastating impact, the pace of new therapy development has remained sluggish — largely due to the high cost, duration, and risks associated with traditional clinical trials. This bottleneck has often discouraged conventional investors, leaving promising research to tackle this challenge, the authors propose an investment fund that finances half the cost of an adaptive platform trial in exchange for future royalties from successful drugs that emerge from the trial. Adaptive platform trials allow multiple drug candidates to be tested simultaneously under a single master protocol and results are interpreted on a real-time basis to determine efficacy or futility. Drawing on data from the HEALEY ALS Platform Trial administered by the Healey & AMG Center for ALS and realistic assumptions, their simulated fund generated an expected return of 28%, with a 22% probability of total loss, which may be attractive to more risk-tolerant and impact-driven investors such as hedge funds, sovereign wealth funds, family offices, and philanthropists. Their findings suggest that generating returns more palatable for mainstream investors could be achieved by funding multiple platform trials simultaneously and by employing financial tools such as securitization — a method that bundles future income from assets like loans or royalties into investment study represents a multidisciplinary collaboration among physicians, clinical trial experts, and financial engineers including Annette De Mattos, Kristin Drake, Merit E. Cudkowicz, Ricardo Ortiz, Meredith Hasenoehrl, Marianne Chase, Brittney Harkey, and Sabrina Paganoni of the Sean M. Healey & AMG Center for ALS at MGH; Eugene Sorets of Questrom School of Business at Boston University; Shomesh Chaudhuri and John Frishkopf of QLS Advisors; and Joonhyuk Cho and Andrew W. Lo of MIT. Their work bridges the gap between biomedicine and capital markets, laying a new path forward for how lifesaving therapies are financed and delivered.'ALS clinical trials face significant hurdles — from high costs and long timelines to limited funding pools,' said Dr. Cudkowicz, Executive Director Mass General Brigham Neuroscience Institute and Director of the Healey & AMG Center for ALS. 'Our platform trial model has already shown that we can test more therapies more efficiently. What's still missing is sustainable financing. This novel approach could be a game-changer, enabling us to launch trials faster, include more promising therapies, and bring us closer to our shared goal: delivering effective treatments to people with ALS as quickly as possible.'Dubbed a 'Fund of Adaptive Royalties' (FAR), this model is uniquely positioned to transform how diseases like ALS are addressed, providing developers with access to shared infrastructure, centralized data analytics, and significantly reduced upfront capital requirements while offering investors a diversified, portfolio-based exposure to multiple drug candidates and the potential for high returns. While their study focused on ALS, the authors believe such a funding model could be applied to other disease areas as well, especially those with well-defined endpoints, where treatment success can be measured clearly and reliably, and few existing therapies.'This financing framework addresses one of the core issues in biomedical innovation — bridging the valley of death between discovery and delivery,' said co-author Lo, MIT Charles E. and Susan T. Harris Professor and director of MIT Sloan's Laboratory for Financial Engineering. 'By aligning incentives between investors and developers and distributing risk across a portfolio of candidates, we can unlock new sources of capital for diseases that urgently need them.' About MIT Sloan School of Management The MIT Sloan School of Management is where smart, independent leaders come together to solve problems, create new organizations, and improve the world. Learn more at About the Sean M. Healey & AMG Center for ALS at Mass General At the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, we are committed to bringing together a global network of scientists, physicians, nurses, foundations, federal agencies, and people living with ALS, their loved ones, and caregivers to accelerate the pace of ALS therapy discovery and in November 2018, the Healey & AMG Center, under the leadership of Merit Cudkowicz, MD, and a Science Advisory Council of international experts, is reimagining how to develop and test the most promising therapies to treat the disease, identify cures and ultimately prevent many clinical trials and lab-based research studies in progress right now, we are ushering in a new phase of ALS treatment and care. Together, we will find the cures. About the Boston University Questrom School of Business Founded in 1913, the Boston University Questrom School of Business is a global top-tier academic research business school. Led by Allen Questrom Professor and Dean Susan Fournier, Questrom develops business leaders who create value for the world. Questrom redefines transformational business programs, strengthens partnerships with the business community, advances the impact of research on business, and manages the school as a high-performing enterprise committed to excellence with a service mindset. Comprising a renowned full-time faculty of 165 researchers, teaching faculty, and accomplished practitioners, Questrom generates insights to address today's business challenges and prepares students with the tools they need to succeed from Day 1 in their professional lives. Questrom's portfolio of academic programs is robust and includes a Top 20 undergraduate program of over 2,200 students; distinctive MBA offerings including 900 students in a full- and part-time MBA, the affordable Online MBA and specialty MBAs in social impact, health, and digital technology; several thriving specialized masters programs in areas including business analytics, mathematical finance, and management studies; and a rigorous PhD program. More than 50,000 Questrom alumni form a powerful global network of leaders driving value creation that changes the world. QUESTROM MEANS BUSINESS. For more information, visit About QLS Advisors QLS is an investment manager that is dedicated to improving outcomes for both patients and investors. We aim to achieve these goals by applying the tools of financial engineering, including modern portfolio theory, machine learning, and healthcare finance to our discretionary investment process. At QLS, we believe that quantitative and fundamental techniques are not mutually exclusive but can be combined to build enhanced portfolios in the healthcare space. Attachment New royalty-based investment model for ALS drug development CONTACT: Casey Bayer MIT Sloan School of Management 914.584.9095 bayerc@ Brandon Chase Sean M. Healey & AMG Center for ALS 413.575.9795 bchase7@ Paul Alexander Boston University Questrom School of Business 617.470.9772 pasystem@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
